Global Interventional Oncology Market Size Study, By Technique, By Procedure, By Application, By End-use, And Regional Forecasts 2022-2032

Description

The global interventional oncology market is valued at USD 2.53 billion in 2023 and is projected to grow at a CAGR of 9% from 2024 to 2032. Interventional oncology is an emerging field in cancer treatment, utilizing minimally invasive techniques such as radiofrequency ablation (RFA), transarterial chemoembolization (TACE), microwave ablation (MWA), and cryoablation. These advanced procedures are gaining prominence as they offer higher precision, reduced patient trauma, and quicker recovery times compared to conventional cancer treatments like surgery, chemotherapy, and radiation therapy.

The market's rapid expansion is fueled by the rising prevalence of cancer, advancements in image-guided procedures, and growing investments in minimally invasive oncology treatments. According to the World Health Organization (WHO), cancer was responsible for 10 million deaths in 2020, making it the second leading cause of mortality worldwide. The increasing burden of cancer worldwide has prompted healthcare providers and companies to develop innovative, effective, and less invasive therapeutic solutions.

The integration of AI, robotics, and real-time imaging technologies in interventional oncology is further enhancing procedural efficiency and patient outcomes. Companies such as Medtronic, Boston Scientific, and Terumo Corporation are investing heavily in R&D for advanced tumor-targeting and ablation solutions. Additionally, government and private funding initiatives are playing a pivotal role in accelerating market growth. For example, Royal Philips, along with its IMAGIO consortium, received a USD 25.97 million grant to support research on minimally invasive cancer treatments. Such investments are expected to drive the adoption of interventional oncology solutions worldwide.

Regional Insights- The North American market dominates the interventional oncology sector, accounting for 37.34% of the global revenue in 2023, driven by the presence of leading medical device companies, high healthcare expenditures, and favorable regulatory policies. The U.S. is witnessing substantial market growth due to the increasing prevalence of hepatocellular carcinoma (HCC) and lung cancer, along with strategic collaborations between research institutions and industry leaders.

In Europe, rising cancer prevalence and a growing emphasis on minimally invasive treatments are propelling market growth. According to the European Commission, 2.7 million people were diagnosed with cancer in 2022, a 2.3% increase from 2020. Additionally, government-backed funding programs and healthcare initiatives are fostering advancements in interventional oncology.

The Asia Pacific region is expected to witness the fastest CAGR of 11.55% from 2024 to 2032, attributed to high cancer incidence rates, expanding healthcare infrastructure, and increasing government initiatives. Countries like China, India, and Japan are experiencing a surge in oncology-focused investments and clinical trials, making the region a hotspot for market expansion and innovation.

Major Market Players Included in this Report:

Medtronic plc
Boston Scientific Corporation
Johnson & Johnson (Ethicon)
Baxter International Inc.
Cook Medical
C.R. Bard Inc. (Acquired by BD)
AngioDynamics Inc.
Stryker Corporation
B. Braun Melsungen AG
Terumo Corporation
Siemens Healthineers
GE Healthcare

The Detailed Segments and Sub-Segments of the Market are Explained Below:

By Technique:

Ablation Therapies
- Radiofrequency Ablation (RFA)
- Microwave Ablation (MWA)
- Cryoablation
- Laser Ablation
- Irreversible Electroporation (IRE)
Embolization Therapies
- Transarterial Chemoembolization (TACE)
- Transarterial Radioembolization (TARE)
Biopsy Techniques
- Core Needle Biopsy
- Fine Needle Aspiration (FNA)
Targeted Therapy Delivery Systems
- Drug-Eluting Beads
- Radioembolization
- Drug-Eluting Stents
- Injectable Hydrogels and Nanoparticles
Image-Guided Procedures
- Ultrasound Guidance
- CT Scan Guidance
- MRI Guidance
- Fluoroscopy Guidance

By Procedure:

Tumor Ablation
Tumor Biopsy
Vascular Interventions
Palliative Care

By Application:

Liver Cancer
Lung Cancer
Kidney Cancer
Prostate Cancer
Breast Cancer
Other Cancers

By End-Use:

Hospitals
Specialty Clinics
Others

By Region:

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Thailand
Latin America
- Brazil
- Argentina
Middle East & Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Years considered for the study are as follows:

Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years (2022-2032).
Annualized revenue and regional-level analysis for each market segment.
Detailed geographical landscape with country-level analysis of major regions.
Competitive landscape with market share insights from leading players.
Analysis of key business strategies and recommendations for future market positioning.
Competitive structure evaluation with SWOT analysis of major companies.
Demand-side and supply-side assessment of the market.

Chapter 1. Global Interventional Oncology Market Executive Summary

1.1. Global Interventional Oncology Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Technique
- 1.3.2. By Procedure
- 1.3.3. By Application
- 1.3.4. By End-Use
1.4. Key Market Trends
1.5. Recession Impact Analysis
1.6. Analyst Recommendations & Conclusion

Chapter 2. Global Interventional Oncology Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply-Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand-Side Analysis
  - 2.3.4.1. Regulatory Frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Environmental Considerations
  - 2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Interventional Oncology Market Dynamics

3.1. Market Drivers
- 3.1.1. Rising Incidence of Cancer Worldwide
- 3.1.2. Increasing Preference for Minimally Invasive Procedures
- 3.1.3. Advancements in Image-Guided Therapies
- 3.1.4. Growing Government & Private Sector Investments in Oncology
3.2. Market Challenges
- 3.2.1. High Cost of Interventional Oncology Procedures
- 3.2.2. Limited Availability of Skilled Professionals
- 3.2.3. Regulatory and Reimbursement Challenges
3.3. Market Opportunities
- 3.3.1. Expansion of Healthcare Infrastructure in Emerging Markets
- 3.3.2. Development of AI & Robotics-Assisted Interventional Oncology
- 3.3.3. Growing Adoption of Combination Therapies

Chapter 4. Industry Analysis

4.1. Porter's Five Forces Analysis
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's Five Forces Model
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economic
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends in Interventional Oncology
4.6. Industry Expert Perspectives
4.7. Analyst Recommendations & Conclusion

Chapter 5. Global Interventional Oncology Market Size & Forecasts by Technique (2022-2032)

5.1. Segment Dashboard
5.2. Global Market Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 5.2.1. Ablation Therapies
  - 5.2.1.1. Radiofrequency Ablation (RFA)
  - 5.2.1.2. Microwave Ablation (MWA)
  - 5.2.1.3. Cryoablation
  - 5.2.1.4. Laser Ablation
  - 5.2.1.5. Irreversible Electroporation (IRE)
- 5.2.2. Embolization Therapies
  - 5.2.2.1. Transarterial Chemoembolization (TACE)
  - 5.2.2.2. Transarterial Radioembolization (TARE)
- 5.2.3. Biopsy Techniques
- 5.2.4. Targeted Therapy Delivery Systems
- 5.2.5. Image-Guided Procedures

Chapter 6. Global Interventional Oncology Market Size & Forecasts by Procedure (2022-2032)

6.1. Segment Dashboard
6.2. Global Market Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 6.2.1. Tumor Ablation
- 6.2.2. Tumor Biopsy
- 6.2.3. Vascular Interventions
- 6.2.4. Palliative Care

Chapter 7. Global Interventional Oncology Market Size & Forecasts by Application (2022-2032)

7.1. Segment Dashboard
7.2. Global Market Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 7.2.1. Liver Cancer
- 7.2.2. Lung Cancer
- 7.2.3. Kidney Cancer
- 7.2.4. Prostate Cancer
- 7.2.5. Breast Cancer
- 7.2.6. Other Cancers

Chapter 8. Global Interventional Oncology Market Size & Forecasts by End-Use (2022-2032)

8.1. Segment Dashboard
8.2. Global Market Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 8.2.1. Hospitals
- 8.2.2. Specialty Clinics
- 8.2.3. Others

Chapter 9. Global Interventional Oncology Market Size & Forecasts by Region (2022-2032)

9.1. North America Market
- 9.1.1. U.S. Market
- 9.1.2. Canada Market
- 9.1.3. Mexico Market
9.2. Europe Market
- 9.2.1. Germany Market
- 9.2.2. UK Market
- 9.2.3. France Market
- 9.2.4. Italy Market
- 9.2.5. Spain Market
- 9.2.6. Denmark Market
- 9.2.7. Sweden Market
- 9.2.8. Norway Market
9.3. Asia-Pacific Market
- 9.3.1. China Market
- 9.3.2. Japan Market
- 9.3.3. India Market
- 9.3.4. South Korea Market
- 9.3.5. Australia Market
- 9.3.6. Thailand Market
9.4. Latin America Market
- 9.4.1. Brazil Market
- 9.4.2. Argentina Market
9.5. Middle East & Africa (MEA) Market
- 9.5.1. South Africa Market
- 9.5.2. Saudi Arabia Market
- 9.5.3. UAE Market
- 9.5.4. Kuwait Market

Chapter 10. Competitive Intelligence

10.1. Key Company SWOT Analysis
- 10.1.1. Medtronic plc
- 10.1.2. Boston Scientific Corporation
- 10.1.3. Terumo Corporation
10.2. Top Market Strategies
10.3. Company Profiles
- 10.3.1. Medtronic plc
- 10.3.2. Boston Scientific Corporation
- 10.3.3. Johnson & Johnson (Ethicon)
- 10.3.4. Baxter International Inc.
- 10.3.5. Cook Medical
- 10.3.6. C.R. Bard Inc. (Acquired by BD)
- 10.3.7. AngioDynamics Inc.
- 10.3.8. Stryker Corporation
- 10.3.9. B. Braun Melsungen AG
- 10.3.10. Siemens Healthineers

Chapter 11. Research Process

11.1. Research Process
- 11.1.1. Data Mining
- 11.1.2. Analysis
- 11.1.3. Market Estimation
- 11.1.4. Validation
- 11.1.5. Publishing
11.2. Research Attributes